Article Details
Retrieved on: 2024-11-30 11:05:28
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Defence Therapeutics Inc.'s plans to license its Accum® technology to boost the efficacy of Antibody Drug Conjugates (ADCs) in biotechnology, relating to tags like 'ADC' and 'biopharmaceutical'. It also details recent warrant offerings.
Article found on: www.newsfilecorp.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here